Last reviewed · How we verify

NCT05764486

A Study About the Operation Efficacy and the Early Stage Safety of Heavy Ion Beam Treatment System in Solid Tumor

Completed NA Last updated 10 March 2023
What this trial tests

NA trial testing Hitachi's Heavy Ion Beam Therapy System HyBEAT in Cancer in 6 participants. Completed in 20 December 2022.

Timeline
21 June 2022
Primary endpoint
20 December 2022
20 December 2022

Quick facts

Lead sponsorTaipei Veterans General Hospital, Taiwan
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment6
Start date21 June 2022
Primary completion20 December 2022
Estimated completion20 December 2022
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Taipei Veterans General Hospital, Taiwan

Who can join

20 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to investigate the safety of Hitachi's Heavy Ion Beam Therapy System HyBEAT for treating patients with solid tumor in Taipei Veterans General Hospital, including patients early-stage adverse reactions and the efficacy on tumors, as well as to assess the operation efficacy of the device.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Taipei Veterans General Hospital, Taiwan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05764486.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing